Clinical trials: Placebo Response
Congenital Bleeding Disorder, Healthy
Dose Response to Recombinant Factor VIIa When Administered for Bleed
This trial is conducted in the United States of America (USA). The purpose of this trial is to investigate the dose response to recombinant factor VIIa in healthy volunteers when administered for bleed.
- Trial name
- NCT00104455
- Testing
- activated recombinant human factor VII
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Hepatitis C, Chronic
GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection
This is a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) Compared with GS-5885, GS-9451 with Tegobuvir or RBV in Treatment-Experienced Subjects with Chronic Genotype…
- Trial name
- NCT01435226
- Testing
- GS-5885, GS-9451, tegobuvir
- Where
- 51 sites in United States, Germany
- Volunteers
- 170 people
- Sponsor
- Gilead Sciences
Painful Diabetic Neuropathy
Efficacy and Safety of MEDI7352 in Participants With Painful Diabetic Neuropathy
This is a study investigating the effect of MEDI7352 on chronic pain in participants with painful diabetic neuropathy. The study incudes a screening period of up to 45 days and a 12-week treatment period during which MEDI7352 or…
- Trial name
- NCT03755934
- Testing
- MEDI7352
- Where
- 31 sites in Denmark, Hungary and 3 more
- Volunteers
- 112 people
- Sponsor
- AstraZeneca
Schizophrenia
Trial Evaluating the Efficacy and Safety of 2 Fixed Doses of Paliperidone Extended-Release (ER) Tablets in the Treatment of Adult Patients With Schizophrenia
The purpose of this trial is to determine if paliperidone ER is an effective treatment for adults with schizophrenia.
- Trial name
- NCT00077714
- Testing
- Paliperidone ER
- Volunteers
- 12 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Healthy Volunteer Safety Study
AB103 Peptide Antagonist in Healthy Volunteers
The primary objective of this study is to establish the safety profile and maximum tolerated dose (MTD) of AB103 given as a single intravenous (IV) infusion in healthy volunteers.
- Trial name
- NCT01166984
- Testing
- AB103
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Atox Bio Ltd
COVID-19
INB03 for the Treatment of Pulmonary Complications From COVID-19
The purpose of this study is to determine whether XPro1595 can prevent the progression of respiratory complications in COVID19 patients.
- Trial name
- NCT04370236
- Testing
- INB03
- Where
- 9 sites in United States
- Volunteers
- 79 people
- Sponsor
- Inmune Bio, Inc.
Chronic Non-specific Low Back Pain
Dose-Response Characterization of VER-01 in the Treatment of Patients With Chronic Non-specific Low Back Pain
Dose-response characterization of VER-01 in patients with chronic non-specific low back pain (CLBP) for whom drug treatment is indicated and previous optimized treatments with non-opioid analgesics have not led to sufficient pain…
- Trial name
- RESPONSE (NCT06475001)
- Testing
- VER-01
- Where
- United Kingdom
- Volunteers
- 652 people
- Sponsor
- Vertanical GmbH
Skin Aging on Face, Skin Care Dermocosmetics
Efficacy of Topical Niacinamide Riboside on the Signs of Facial Skin Aging
Niacinamide riboside (topical NR, also known as nicotinamide riboside) is an endogenous compound and a precursor (building block) to the essential cellular co-enzyme, nicotinamide adenine dinucleotide (NAD+).
- Conditions
- Skin Aging on Face, Skin Care Dermocosmetics, Skin Care, Fine Lines and Wrinkles
- Trial name
- NR-RADIANCE (NCT07774000)
- Testing
- Topical niacinamide riboside
- Where
- South Africa
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- ChromaDex, Inc.
Nocturia
Comparative Trial to Investigate the Dose-Response of 4 Different Dose Levels of Minirin Melt and Placebo
This is a multi-centre, randomised, placebo-controlled, double-blind, parallel-group comparative trial to be conducted in nocturia patients.
- Trial name
- NOC (NCT01184859)
- Testing
- Desmopressin
- Where
- 36 sites in Japan
- Volunteers
- 116 people
- Sponsor
- Ferring Pharmaceuticals
Asthma
Study Evaluating the Effects of AIR645 on Allergen-Induced Airway Responses in Subjects With Mild Atopic Asthma
To assess the efficacy of inhaled AIR645 in the suppression of the Asthmatic Responses in subjects with mild asthma inhaling an allergen.
- Trial name
- NCT00941577
- Testing
- AIR645, Physiologic saline solution
- Where
- 3 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Altair Therapeutics, Inc.
Severe Sepsis, Septic Shock
A Study to Assess Safety,and Tolerability of 2 Doses of AZD9773 (CytoFab™) in Japanese With Severe Sepsis/Septic Shock
The two co-primary objectives of this study are to assess in Japanese patients with severe sepsis and/or septic shock: 1) the safety and tolerability of two different doses of intravenous AZD9773 and 2) the PK of AZD9773.
- Trial name
- NCT01144624
- Testing
- AZD9773
- Where
- 7 sites in Japan
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
Breast Density
Effect of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast Density
This is a randomized, double-blinded, placebo-controlled dose-response efficacy study of oral (Z)-endoxifen in premenopausal women with measurable breast density.
- Trial name
- NCT05068388
- Testing
- Z-Endoxifen
- Where
- Sweden
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Atossa Therapeutics, Inc.
SARS-CoV Infection, Covid19
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2
This is a phase 3, randomized, observer-blinded, placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of SARS-CoV-2 rS with Matrix-M1 adjuvant in adult participants and adolescent participants.
- Trial name
- NCT04611802
- Testing
- SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)
- Where
- 154 sites in United States, Mexico and 1 more
- Volunteers
- 33,000 people, healthy volunteers welcome
- Sponsor
- Novavax
Perioperative Pain
Dose-Response of Adenosine for Perioperative Pain
Adenosine A1 and A2 receptors are widely distributed in the brain and spinal cord and represent a non-opiate target for pain management.
- Trial name
- NCT00298636
- Testing
- adenosine
- Where
- 8 sites in United States
- Volunteers
- 160 people
- Sponsor
- Xsira Pharmaceuticals
Obesity
A Study on Efficacy and Safety of Topiramate in the Treatment of Patients With Obesity
The purpose of this study is to compare the efficacy and safety of topiramate (96, 192, and 256mg daily) with placebo in long-term treatment of obesity.
- Trial name
- NCT00236639
- Testing
- topiramate
- Volunteers
- 1,293 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sepsis and Coagulopathy
The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy
The purpose of the study is to evaluate if ART-123 given to patients who have severe sepsis can decrease mortality.
- Trial name
- Scarlet2 (NCT03517501)
- Testing
- ART-123
- Sponsor
- Asahi Kasei Pharma America Corporation
Hodgkin's Lymphoma
A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)
The primary objective was to provide drug to ongoing patients who were receiving panobinostat and to characterize the safety and tolerability of panobinostat in patients with HL after achieving a complete response following…
- Trial name
- PATH (NCT01034163)
- Testing
- Panobinostat
- Where
- 35 sites in United States, Australia and 12 more
- Volunteers
- 41 people
- Sponsor
- Novartis Pharmaceuticals
Lupus Nephritis
Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin
The purpose of this study is assess the long-term safety and tolerability of voclosporin compared with placebo for up to an additional 24 months following completion of treatment in the AURORA 1 study in subjects with lupus…
- Trial name
- AURORA 2 (NCT03597464)
- Testing
- Voclosporin
- Where
- United States
- Volunteers
- 216 people
- Sponsor
- Aurinia Pharmaceuticals Inc.
Post-herpetic Neuralgia
Dose Response Study of EMA401 in Patients With Post-herpetic Neuralgia (PHN)
This study was designed to characterize dose response, and evaluate safety and efficacy of three different doses of EMA401 compared to placebo in patients with post-herpetic neuralgia (PHN).
- Trial name
- EMPHENE (NCT03094195)
- Testing
- EMA401
- Where
- 58 sites in Australia, Austria and 17 more
- Volunteers
- 130 people
- Sponsor
- Novartis Pharmaceuticals
Staphylococcus Aureus
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of AZD7760 when given as an intravenous infusion to healthy participants (Phase I) or participants with end-stage kidney disease receiving hemodialysis…
- Trial name
- PEAK (NCT06749457)
- Testing
- AZD7760
- Where
- 40 sites in United States
- Volunteers
- 242 people, healthy volunteers welcome
- Sponsor
- AstraZeneca